Drug Patent Watch

JANUARY 2, 2020

Here’s a copy of the recent talk on Evaluating innovative portfolios and preparing for branded, 505(b)(2), and generic competition. It’s based on the book Make Better Decisions, which distills insights…. The post Evaluating innovative portfolios and preparing for branded, 505(b)(2), and generic competition appeared first on DrugPatentWatch - Make Better Decisions.

69

69

Pharma Packaging Solutions

JANUARY 27, 2020

Happy 2020! There is something about a new decade that brings a sharper focus on the future. At Pharma Packaging Solutions, we are celebrating 25 years of pharmaceutical packaging experience and now we look forward to the next 25 years. Our 1995 facility addition in East Tennessee and focus on pharmaceutical packaging has been a journey through myriad technical challenges, a learning curve through regulatory change, and a pleasure through many customer success stories.

Packaging 52

Packaging Labelling 52

Med Ed 101

JANUARY 29, 2020

YS is a 79-year-old female with a medical history of osteoarthritis, insomnia, CVD, GERD, constipation, dementia, and falls. Her current medication list includes donepezil, Senna-S, lisinopril, zolpidem, amitriptyline, baby aspirin, acetaminophen, and omeprazole. Over the last three months, she has had a total of 7 falls and one that resulted in a fractured wrist.

40

40

Med Ed 101

JANUARY 26, 2020

I recently received a text from a friend about the use of oral semaglutide in a patient with diabetes. It is definitely exciting to have more options for patients, even though we know there will inevitably be insurance coverage hurdles to jump through. Here are a few things that you should remember about this first […]. The post Oral Semaglutide Clinical Pearls appeared first on Med Ed 101.

Diabetes 40

Diabetes 40

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Med Ed 101

JANUARY 22, 2020

Oftentimes there are numerous agents within a class of medication. Ropinirole (Requip) and pramipexole (Mirapex) is an example of this. When comparing ropinirole and pramipexole, there are clinical differences that might alter which one you choose. Comparing Ropinirole and Pramipexole Pharmacokinetics The most obvious difference when comparing ropinirole and pramipexole involves pharmacokinetic differences.

40

40

Med Ed 101

JANUARY 19, 2020

FDA Approval The FDA has recently approved two generic versions of apixaban and from the amount of apixaban I’m seeing used in clinical practice, this is a great thing for overall healthcare and drug costs. Here’s the FDA’s statement. Because of this switch to generic apixaban availability as well as the recent 2019 atrial fibrillation […].

40

40

Med Ed 101

JANUARY 8, 2020

Diclofenac gel can be a beneficial tool in the management of localized osteoarthritis pain. There are many situations where acetaminophen is not effective and oral NSAIDs are intolerable or inappropriate. This is a type of situation where diclofenac gel may be appropriate to consider. Here are a few mistakes and clinical pearls that you should […].

40

40

Med Ed 101

JANUARY 1, 2020

Much like the BCPS exam, the BCACP (Board Certified Ambulatory Care Pharmacist) exam is undergoing changes for the fall of 2020. (If you are looking for a breakdown of the BCPS 2020 Changes, find them here.) BCACP exam changes likely include a significantly greater emphasis on ambulatory care and clinical topics. This is a welcomed […]. The post BCACP Exam Changes for Fall of 2020 appeared first on Med Ed 101.

40

40

Med Ed 101

JANUARY 15, 2020

2020 Pharmacist Provider Status is being considered by the Trump administration. This is a good thing for the profession and more importantly, a good thing for patients. There were a couple of quotes from CMS Administrator Seema Verma with regards to provider status that really demonstrates that it could be on the way. Here are […]. The post 2020 Pharmacist Provider Status.

40

40